Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal remimazolam soft-mist sedation study
NL-OMON60422Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remimazolam, sponsored by Radboud University Medical Center. Primary endpoint: Maximum decrease in Bispectral Index. Started Mar 2025; status: completed.
02
Drugs
remimazolam
Beyond the preview
Go deeper on NL-OMON60422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60422.